+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of acute myeloblastic leukemia in adults. The GOELAM experience



Treatment of acute myeloblastic leukemia in adults. The GOELAM experience



Hematology & Cell Therapy 38(5): 381-391



The GOELAM group conducted 2 consecutive trials on the treatment of de novo acute myeloblastic leukemia (AML) in adults. In the GOELAM1 protocol 786 patients aged 15-65 were randomized between two induction treatments (ARA-C 200 mg/m2/day for 7 days plus either Idarubicin 8 mg/m2/day for 5 days or Rubidazone 200 mg/m2/day for 4 days). Out of 731 evaluable patients, 521 (71%) achieved complete remission (CR) without significant difference between the 2 anthracyclines. For patients aged 51-65, the CR rate was significantly higher with Idarubicin (75%) than with Rubidazone (61%) (p = 0.03). In this group of patients the post-remission therapy consisted in only one course of high dose ARA-C plus m-Amsa and the 6 year disease free survival (DFS) was 24% (intention to treat analysis). For patients aged 15-50 years, the post remission therapy was either allogeneic bone marrow transplantation (BMT) (patients up to 40 years of age with an HLA identical sibling) or a first course of intensive consolidation chemotherapy (ICC) followed by a randomization between autologous unpurged bone marrow transplantation (ABMT) and a second course of ICC. There was no significant difference in the 4 year DFS between allogeneic BMT (42%) and the other types of intensive post remission-therapy (40%). The 4 year DFS was 42% for ABMT and 38% for ICC (p = 0.46) (intention to treat analysis). However the median duration of thrombocytopenia was much longer after ABMT (109.5 days versus 18.5 days p = 0.0001). The GOELAM SA3 randomized placebo-controlled protocol tested the impact of GM-CSF given during and after induction treatment for elderly patients (55-75 years). In this study, 232 evaluable patients received induction chemotherapy (Idarubicin 8 mg/m2/day for 5 days plus ARA-C 100 mg/m2/day for 7 days) plus placebo or GM-CSF 5 micrograms/kg/day from day 1 until the end of neutropenia. The CR rate was 61.5%. The median duration of neutropenia was shorter in the GM-CSF arm (22 days versus 27 days p = 0.0001). There was no overall significant advantage for the GM-CSF arm, in terms of CR rate and survival. However for patients age 55-64 the 2 year DFS was significantly higher in the GM-CSF arm (43% vs 17% p = 0.0013).

(PDF emailed within 0-6 h: $19.90)

Accession: 009671706

Download citation: RISBibTeXText

PMID: 8915668

DOI: 10.1007/s00282-996-0381-5


Related references

Treatment of acute myeloid leukemia younger adults: the GOELAM experience. Annals of Hematology 83 Suppl 1: S104-S105, 2004

Induction followed by intensive and unique consolidation for acute myeloblastic leukemia between the ages of 50 and 65 Experience of the GOELAM group. Nouvelle Revue Francaise d'Hematologie 35(3): 336, 1993

Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3. Therapie 56(2): 131-133, 2001

Comparison between bone marrow autograft and intensive chemotherapy as treatment for maintenance of complete remission in acute myeloblastic leukemia in the adult. GOELAM Group. Nouvelle Revue Francaise d'Hematologie 35(3): 197-198, 1993

Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer 71(10 Suppl): 3377-3385, 1993

Autologous bone marrow transplantation versus intensive consolidation chemotherapy as post remission therapy in adult acute myeloblastic leukemia Final analysis of the GOELAM randomized study. British Journal of Haematology 93(SUPPL 2): 133, 1996

Our experience in the treatment of acute myeloblastic leukemia. Minerva Pediatrica 26(34): 1744-1747, 1974

Treatment of acute myeloblastic leukemia in adults with 2-chlorodeoxyadenosine. Blood 82(10 SUPPL 1): 129A, 1993

Methylglyoxal bis , NSC-32946, in the treatment of acute myeloblastic and monoblastic leukemia in adults. Cancer Chemother Rept 36: 63-71, 1964

Episodes of fever in the agranulocytic phase of the treatment of acute myeloblastic leukemia in adults. La Semaine des Hopitaux 52(2): 111-113, 1976

Treatment of acute myeloblastic leukemia in adults current status and future prospects. Australian & New Zealand Journal of Medicine 14(6 SUPPL 4): 947, 1984

Methylglyoxal Bis(Guanylhydrazone), Nsc-32946, 1 in the Treatment of Acute Myeloblastic and Monoblastic Leukemia in Adults. Cancer ChemoTherapy Reports 36: 63-71, 1964

N acetyl beta d glucosaminidase enzymuria in leukemia and myelomatosis effect of treatment in acute myeloblastic leukemia and myelomatosis in adults. Annals of Clinical Biochemistry 23(6): 676-680, 1986

Treatment of acute myeloblastic leukemia in adults: remission induction with a combination of cyclophosphamide, cytarabine and vincristine. Canadian Medical Association Journal 107(11): 1073-1078, 1972

Experience with four consecutive BFM-based protocols for treatment of childhood with non-promyelocytic acute myeloblastic leukemia in Argentina. Leukemia and Lymphoma 57(9): 2090-2099, 2018